Yesterday, mid cap women�� health stock Hologic, Inc (NASDAQ: HOLX) fell more than 10% after disappointing Wall Street on earnings,�meaning it might be time to take a look at it and�small cap women�� health stocks�The Female Health Company (NASDAQ: FHCO) and TherapeuticsMD Inc (NYSEMKT: TXMD) because after all, women account for half the population and these three small caps are all focused on the women�� health:
Hologic, Inc.�A leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products, Hologic, Inc has�an emphasis on serving the healthcare needs of women throughout the world. On Monday after the market closed, Hologic, Inc�announced that fiscal�fourth quarter revenues increased 5.7% to $622.1 million along with a�9.4% increase in non-GAAP net income�to $107.6 million and a net loss�of $1.1 billion verses a�net loss of $77.8 million as the company determined that goodwill within its Diagnostics business segment was impaired. Weak demand for the ThinPrep pap tests, the mammography system 2D Selenia and the heavy menstruation surgical solution NovaSure impacted the top line. Given the deterioration of the ThinPrep and NovaSure lines, which�are Hologic, Inc�� most profitable businesses,�analysts range from being skeptical�or at least more realistic about the company�� prospects with a Jefferies report saying: ��
Top 10 Shipping Stocks To Invest In Right Now: OmniVision Technologies Inc.(OVTI)
OmniVision Technologies, Inc. designs, develops, and markets semiconductor image-sensor devices. The company offers CameraChip image sensors, which are single-chip solutions that integrate various functions, such as image capture, image processing, color processing, signal conversion, and output of a processed image or video stream for use in various consumer and commercial mass-market applications; and CameraCube imaging devices that are image sensors with integrated wafer-level optics. It also provides companion chips used to connect its image sensors to various interfaces, including the universal serial bus and other industry standard interfaces; and companion digital signal processors that perform compression in standardized still photo and digital video formats. In addition, the company designs and develops software drivers for Linux, Mac OS, and Microsoft Windows, as well as for embedded operating systems, such as Blackberry OS, Palm OS, Symbian, Windows CE, Windows Embedded, and Windows Mobile. Its products are used in mobile phones, notebooks, Webcams, digital still and video cameras, commercial and security and surveillance, and automotive and medical applications, as well as in entertainment devices. The company sells its products directly to original equipment manufacturers and value added resellers, as well as indirectly through distributors worldwide. OmniVision Technologies, Inc. was founded in 1995 and is based in Santa Clara, California.
Advisors' Opinion:- [By Dan Caplinger]
But if you expand your view of the market, you'll find plenty of big movers and more interesting goings-on. OmniVision Technologies (NASDAQ: OVTI ) is the big winner this afternoon, soaring more than 19% in the wake of last night's positive earnings report. OmniVision said its cost-reduction strategy had started to bear fruit, revealing a combination of favorable results for its most recent quarter and expectation-beating guidance for the current quarter. In the long run, OmniVision has to demonstrate its ability to keep its image-sensor chips in the most popular smartphones, tablets, and other mobile devices. So far, though, investors are content with the growth they've seen.
- [By Rick Munarriz]
Briefly in the news
OmniVision (NASDAQ: OVTI ) investors are seeing the big picture. Shares of the image sensor maker moved higher after posting better-than-expected quarterly results. Revenue soared 54%, and OmniVision's profit of $0.31 a share blew away the $0.21 analysts were targeting. Nokia (NYSE: NOK ) is no longer the leading smartphone seller in Finland. Tech tracker IDC reports that Samsung outsold Nokia in its home country this past quarter. So much for the hometown hero. Vringo (NASDAQ: VRNG ) got another tech giant to pay up, but it won't be much. The company announced a patent-infringement settlement with Mr. Softy in which Vringo will receive $1 million and enter into a licensing deal with the world's largest software company.
And now let's take a quick look at some of the other stories that shaped our week. - [By Laura Brodbeck]
Tuesday
Earnings Expected From: Bank of Montreal (NYSE: BMO), United Natural Foods, Inc. (NASDAQ: UNFI), OmniVision Technology, Inc. (NASDAQ: OVTI), Universal Technical Institute, Inc. (NYSE: UTI) Economic Releases Expected: Chinese HSBC Services PMI, Australian GDP, Brazilian GDP, eurozone PPI, British construction PMI.Wednesday
5 Best Small Cap Stocks To Buy Right Now: EZchip Semiconductor Limited(EZCH)
EZchip, a fabless semiconductor company, engages in the development and marketing of Ethernet network processors for networking equipment. Its products include network processor chips, evaluation boards and network-processor based systems, and development software toolkits. The company offers network processors for use in forming the silicon core of networking equipment, such as switches and routers; and for voice, video and data integration in various applications. Its network processors are single-chip solutions, which enable its customers to design multi-port line cards, such as processing and classification engines, traffic managers, media access controllers, as well as a range of specialized hardware blocks that accelerate various functions. The company offers Evaluation systems which enable customers to test NPU-based systems; and toolkits that assist customers in creating, verifying, and implementing solutions based on its network processors. It provides a library f eaturing data plane code for a range of applications, which include Metro Ethernet protocols, Multi-Protocol Label Switching, IPv4 and IPv6 routing, Access Control Lists, GPON/EPON OLT functionality, Network Address Translation, and Server Load Balancing. The company sells its products directly, and through contract manufacturers and distributors to network equipment vendors. It markets its products in Israel, China, Hong Kong, the Far East, Canada, the United States, and Europe. The company was formerly known as LanOptics Ltd. and changed its name to EZchip Semiconductor Ltd. in July 2008. EZchip Semiconductor Ltd. was founded in 1989 and is based in Yokneam, Israel.
Advisors' Opinion:- [By Paul McWilliams]
Paul McWilliams: Oh, absolutely. Another company that most investors probably have never heard of is a tiny little Israeli semiconductor company named EZChip (EZCH).
- [By Lisa Levin]
EZchip Semiconductor (NASDAQ: EZCH) shares climbed 5.80% to $23.53. The volume of EZchip Semiconductor shares traded was 635% higher than normal. EZchip Semiconductor's PEG ratio is 1.57.
5 Best Small Cap Stocks To Buy Right Now: Petroquest Energy Inc(PQ)
PetroQuest Energy, Inc. operates as an independent oil and gas company. It engages in the acquisition, exploration, development, and operation of oil and gas properties in Oklahoma, Arkansas, and Texas, as well as onshore and in the shallow waters offshore the Gulf Coast Basin. As of December 31, 2009, the company had estimated proved reserves of 1,931 thousand barrels of oil and 167,361 million cubic feet equivalent of natural gas. It owned working interests in 9 net producing oil wells and 277 net producing gas wells. PetroQuest Energy was founded in 1983 and is headquartered in Lafayette, Louisiana.
Advisors' Opinion:- [By Jon C. Ogg]
PetroQuest Energy Inc. (NYSE: PQ) was downgraded to Neutral from Overweight at J.P. Morgan.
Rubicon Technology Inc. (NASDAQ: RBCN) was downgraded to Underperform from Perform at Oppenheimer.
5 Best Small Cap Stocks To Buy Right Now: Achillion Pharmaceuticals Inc.(ACHN)
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. The company focuses on the development of antivirals for the treatment of chronic hepatitis C; and the development of antibacterials for the treatment of resistant bacterial infections. Its drug candidates for the treatment of chronic HCV include ACH-1625, a protease inhibitor, which is in phase IIa clinical trial for the treatment of chronic HCV; ACH-2684, a pangenotypic protease inhibitor, which is in phase I clinical trial for the treatment of chronic HCV infection; and NS5A inhibitors for the treatment of chronic HCV infection, including ACH-2928, which is to enter a phase I clinical trial, as well as various additional NS5A inhibitors in preclinical development. Its pipeline of product candidates also includes ACH-702 and ACH-2881 for drug resistant bacterial infections; elvucitabine for HIV infection; and AC H-1095 for HCV infection. The company was founded in 1998 and is based in New Haven, Connecticut.
Advisors' Opinion:- [By Sean Williams]
The latest hepatitis-C nightmare came from Achillion Pharmaceuticals (NASDAQ: ACHN ) which plunged 24% on the week after the FDA placed a clinical hold on its lead compound, sovaprevir (previously known as ACH-1625) because of a worrisome drug-to-drug interaction noted in early stage trials. According to Achillion's update, sovaprevir, when studied with atazanavir, was associated with elevated ALT enzymes in the liver, although no serious adverse events were documented. Even though the FDA is allowing Achillion to continue studying sovaprevir in its mid-stage trial with ACH-3102, it's just another setback for Achillion which is miles behind Gilead Sciences�and AbbVie�in terms of time it will take to bring a new hepatitis-C therapy to market.
- [By Keith Speights]
2. Achillion Pharmaceuticals (NASDAQ: ACHN )
Achillion recently experienced a delay in the game that it had hoped to play. The FDA placed a clinical hold on hepatitis C drug sovaprevir after patients in a phase 1 drug-drug interaction study with the drug combined with ritonavir-boosted atazanavir were found to have elevated liver enzyme levels. Shares dropped 25% in one day as a result. - [By Grace L. Williams]
We took a look at Achillion Pharmaceuticals (ACHN) after two directors bought 40,000 shares for $394,800. Dennis Liotta bought 20,000 shares for $158,100 and Jason Fisherman bought 20,000 shares for $155,000. InsiderScore gave Liotta a nod, writing, ��iotta has been a smart buyer at Achillion in the past. He bought the same number of shares here, this time at a price 28% higher, which is the highest price he has paid for shares.��/p>
No comments:
Post a Comment